---
title: "Lysergide (DT120) in Generalized anxiety disorder: Diagnosis"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Diagnosis. Topics: DSM-5 diagnostic criteria for generalized anxiety disorder, Clinical diagnosis without a biomarker, Structured interviews and rating scales, Identification and assessment: NICE clinical guideline CG113, and 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/diagnosis"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### DSM-5 diagnostic criteria for generalized anxiety disorder

| Criterion | Quoted text |
| --- | --- |
| A: excessive anxiety and worry | “Excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 months, about a number of events or activities (such as work or school performance).” |
| B: difficulty controlling worry | “The individual finds it difficult to control the worry.” |
| C: associated symptoms | “The anxiety and worry are associated with three (or more) of the following six symptoms (with at least some symptoms having been present for more days than not for the past 6 months):” |
| C1 | “Restlessness or feeling keyed up or on edge.” |
| C2 | “Being easily fatigued.” |
| C3 | “Difficulty concentrating or mind going blank.” |
| C4 | “Irritability.” |
| C5 | “Muscle tension.” |
| C6 | “Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep).” |
| D: distress or impairment | “The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.” |
| E: substance and medical exclusion | “The disturbance is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition (e.g., hyperthyroidism).” |
| F: other mental disorder exclusion | “The disturbance is not better explained by another mental disorder” |

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.1.5-2"></a>

### Clinical diagnosis without a biomarker

> “Because no blood, genetic, or imaging biomarkers exist, diagnosis rests on mental-state history and examinations, which should therefore be sufficiently monitored by every primary care practitioner.”
> “Categorical diagnostic criteria are clinically useful, but boundaries between anxiety disorders and normative anxiety are often ill-defined. Recognition of distinctions requires clinical judgement of severity, duration, persistence, and, importantly, degree of distress and impairment.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.5-3"></a>

### Structured interviews and rating scales

> “Validated, structured, or semi-structured clinical interviews, such as the DSM-5-based or ICD-11-based composite international diagnostic interview9 or structured clinical interview for DSM disorders,10 can assist in correct diagnostics.”
> “To determine the severity of anxiety disorders and monitor treatment, continuous clinician-rated scales include, for example, the Hamilton Anxiety Scale.”
> “Standardised diagnostics and assessments for outcome monitoring are part of evidence-based care, could prevent underdiagnosis, and lead to effective treatments. However, these diagnostics and assessments are still not widely used in clinical practice.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “Numerous scales have been developed to assess symptom severity and support diagnosis. The Generalized Anxiety Disorder 7-item scale (GAD-7) has been validated as a diagnostic and severity assessment tool.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.5-4"></a>

### Identification and assessment: NICE clinical guideline CG113

> “Be alert to possible anxiety disorders (particularly in people with a past history of an anxiety disorder, possible somatic symptoms of an anxiety disorder or in those who have experienced a recent traumatic event). Consider asking the person about their feelings of anxiety and their ability to stop or control worry, using the 2-item Generalized Anxiety Disorder scale (GAD-2).”
> “Consider the diagnosis of GAD in people presenting with anxiety or significant worry, and in people who attend primary care frequently who:”
> “For people who may have GAD, conduct a comprehensive assessment that does not rely solely on the number, severity and duration of symptoms, but also considers the degree of distress and functional impairment.”
> “For people with GAD and a comorbid depressive or other anxiety disorder, treat the primary disorder first (that is, the 1 that is more severe and in which it is more likely that treatment will improve overall functioning).”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.1.5-5"></a>

### Exclusion of medical causes and differential diagnosis

> “Initial assessment begins with evaluation of behavioral or somatic symptoms.”
> “The medical history should include previous trauma, psychiatric conditions, and substance use disorder.”
> “The following tests may be obtained to exclude medical causes: Thyroid function tests Blood glucose level Echocardiography Toxicology screen”
> “The differential diagnoses for generalized anxiety disorder include the following: Hyperthyroidism Pheochromocytoma Chronic obstructive pulmonary disease Transient ischemic attack Epilepsy Bipolar disorder Use of caffeine, decongestants, and albuterol”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “The symptoms of GAD and PD can suggest medical diagnoses, including hyperthyroidism, arrhythmias, asthma, chronic obstructive pulmonary disease, certain medication use or withdrawal (e.g., albuterol, levothyroxine, decongestants, antidepressants, antianxiety medications), and substance use or withdrawal (e.g., caffeine, alcohol, cocaine, amphetamines, cannabinoids).”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “For any patient presenting with increased pathological anxiety, a thorough psychiatric and somatic evaluation should consider whether symptoms reflect other health conditions or effects of substance or medication use.”
> “Laboratory assessment of plasma thyroid-stimulating hormone”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.5-6"></a>

### Screening of adults: USPSTF recommendation, June 2023

> “Adults 64 years or younger, including pregnant and postpartum persons: Screen for anxiety. Grade: B”
> “The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for anxiety disorders in older adults.”
> “Anxiety screening tools alone are insufficient to diagnose anxiety disorders. If a screening test result is positive for an anxiety disorder, a confirmatory diagnostic assessment is needed.”
> “The USPSTF found no evidence on the optimal frequency of screening for anxiety disorders.”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

<a id="topic-2.2.1.5-7"></a>

### Screening of adults: AFP review statement, August 2022, before the USPSTF recommendation of June 2023

> “There is insufficient evidence to support universal screening for GAD or PD in adults at this time; however, the U.S. Preventive Services Task Force is updating guidelines regarding screening for anxiety, suicidality, and depression.”
> “Evaluation for GAD should be considered for patients who express anxiety, pervasive worry, or recurrent somatic symptoms not related to an underlying physical condition.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.1.5-8"></a>

### Accuracy of the GAD-7 and GAD-2 screening instruments

> “A criterion-standard study was performed in 15 primary care clinics in the United States from November 2004 through June 2005.”
> “A cut point was identified that optimized sensitivity (89%) and specificity (82%).”

Source: [Spitzer et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16717171/)

> “A total of 12 samples were identified involving 5223 participants; 11 samples provided data on the accuracy of the GAD-7 for identifying generalized anxiety disorder (GAD).”
> “Pooled sensitivity and specificity values appeared acceptable at a cutoff point of 8 [sensitivity: 0.83 (95% CI 0.71-0.91), specificity: 0.84 (95% CI 0.70-0.92)] although cutoff scores 7-10 also had similar pooled estimates of sensitivity/specificity.”
> “Pooled sensitivity and specificity values appeared acceptable at a cutoff of 3 [sensitivity: 0.76 (95% CI 0.55-0.89), specificity: 0.81 (95% CI 0.60-0.92)].”

Source: [Plummer et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26719105/)

> “At a cutoff of 10 or greater, the pooled sensitivity to detect generalized anxiety disorder was 0.79 (95% CI, 0.65-0.94; I2 = 77.3%) and the pooled specificity was 0.89 (95% CI, 0.83-0.94; I2 = 94.8%).”
> “At lower cutoffs (≥8; ≥9), sensitivity increased and specificity decreased. In general, the GAD-7 performed as well or better than the GAD-2.”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

> “Brief screening measures applied in primary care, such as the Generalized Anxiety Disorder-7, can aid in diagnosis of anxiety disorders (sensitivity, 57.6% to 93.9%; specificity, 61% to 97%).”

Source: [Szuhany and Simon (2022)](https://pubmed.ncbi.nlm.nih.gov/36573969/)

<a id="topic-2.2.1.5-9"></a>

### Detection and treatment gaps in primary care

> “Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder”
> “Many patients (41%) with an anxiety disorder reported no current treatment.”
> “Receiver-operating characteristic curve analysis showed that both the GAD-7 scale and its 2 core items (GAD-2) performed well (area under the curve, 0.80 to 0.91) as screening tools for all 4 anxiety disorders.”

Source: [Kroenke et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17339617/)

> “Anxiety disorders are often unrecognized in primary care settings and years-long delays in treatment initiation occur.”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

> “Monitoring is particularly important because patients who have anxiety disorders often present symptoms other than clear anxiety symptoms”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

Additional sources: [Stein and Sareen (2015)](https://pubmed.ncbi.nlm.nih.gov/26580998/); [Hamilton (1959)](https://pubmed.ncbi.nlm.nih.gov/13638508/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
